News Wire

Eric H. Schultz, the president and CEO of Harvard Pilgrim for the past eight years, resigned today for behavior that he described in his resignation letter as “inconsistent with my personal core values and the company’s core values.” Full text of the letter is pasted in below.

U.S. lawmakers fear the FDA is not doing enough to stop the flow of illegal drugs into the United States as the country works to combat the opioid epidemic, Reuters reports.

The FDA has cleared a new auricular neurostimulation device (Drug Relief, DyAnsys, Inc.), to be used as an aid to reduce the symptoms of opioid withdrawal without narcotics. The device is available for providers to prescribe for use during opioid detoxification.

A new study from University of Illinois at Chicago (UIC) researchers suggests that more than one-third of U.S. adults may be using prescription medications that have the potential to cause depression or increase the risk of suicide, and that because these medications are common and often have nothing to do with depression, patients and health care providers may be unaware of the risk.

Eli Lilly and AstraZeneca have announced that they will discontinue phase 3 trials of their BACE inhibitor lanabecestat for the treatment of Alzheimer's disease, according to a BioPharma Dive report. The AMARANTH study in early Alzheimer's disease, its extension study, as well as the DAYBREAK-ALZ trial in mild Alzheimer's disease dementia will all be stopped.

The Trump administration is urging states to better use Medicaid for the delicate and difficult treatment of opioid-addicted and exposed infants, but did not offer any new outlets, according to a recent FierceHealthcare report.

Congress, however, might be delivering on that front shortly.

The FDA has approved Fulphila (pegfilgrastim-jmdb, Mylan GmbH) as the first biosimilar to Amgen’s Neulasta (pegfilgrastim) to decrease the chance of infection as suggested by febrile neutropenia (fever, often with other signs of infection, associated with an abnormally low number of infection-fighting white blood cells), in patients with nonmyeloid (non-bone marrow) cancer who are receiving mye

In an effort to increase competition and bring down prescription drug prices, FDA Commissioner Scott Gottlieb, MD, wants to speed approval times for rivals to promising new first-to-market medicines, Reuters reports.

New research indicates that millions of Americans may need to talk to their doctor about taking different prescriptions of aspirin, statins, and blood pressure medications, according to a study led by Stanford researchers.

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments. This patient received the treatment in a clinical trial led by Steven A. Rosenberg, MD, PhD, Chief of the Surgery Branch at NCI’s Center for Cancer Research (CCR).

The FDA has approved an additional indication for tofacitinib (Xeljanz, Pfizer). The drug is approved for administration at 10 mg twice daily for at least eight weeks, followed by 5 mg twice daily or 10 mg twice daily, for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital and the University of Toronto.

The FDA is warning consumers that over-the-counter (OTC) teething products containing benzocaine pose a serious risk to infants and children.

The FDA has approved pegvaliase-pqpz (Palynziq, BioMarin Pharmaceutical, Inc.) for adults with a rare and serious genetic disease known as phenylketonuria (PKU). Patients with PKU are born with an inability to break down phenylalanine (Phe), an amino acid present in protein-containing foods and high-intensity sweeteners used in a variety of foods and beverages.

U.S. health authorities are preparing to send an experimental Ebola treatment to the Democratic Republic of Congo for use in a clinical trial aimed at stemming an outbreak in the country that has spread to Mbandaka, a city of about 1.5 million people, Reuters reports.